CL2023001836A1 - Tratamiento de glomerulopatía c3 usando un inhibidor de c5a - Google Patents

Tratamiento de glomerulopatía c3 usando un inhibidor de c5a

Info

Publication number
CL2023001836A1
CL2023001836A1 CL2023001836A CL2023001836A CL2023001836A1 CL 2023001836 A1 CL2023001836 A1 CL 2023001836A1 CL 2023001836 A CL2023001836 A CL 2023001836A CL 2023001836 A CL2023001836 A CL 2023001836A CL 2023001836 A1 CL2023001836 A1 CL 2023001836A1
Authority
CL
Chile
Prior art keywords
glomerulopathy
inhibitor
treatment
susceptible
administering
Prior art date
Application number
CL2023001836A
Other languages
English (en)
Inventor
STAEHR Peter
J Bekker Petrus
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CL2023001836A1 publication Critical patent/CL2023001836A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods of treating certain human patient populations suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
CL2023001836A 2020-12-21 2023-06-20 Tratamiento de glomerulopatía c3 usando un inhibidor de c5a CL2023001836A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063128397P 2020-12-21 2020-12-21

Publications (1)

Publication Number Publication Date
CL2023001836A1 true CL2023001836A1 (es) 2023-11-17

Family

ID=82159849

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001836A CL2023001836A1 (es) 2020-12-21 2023-06-20 Tratamiento de glomerulopatía c3 usando un inhibidor de c5a

Country Status (12)

Country Link
US (1) US20220257580A1 (es)
EP (1) EP4262800A1 (es)
JP (1) JP2024500752A (es)
KR (1) KR20230124981A (es)
CN (1) CN116635075A (es)
AU (1) AU2021410668A1 (es)
CA (1) CA3205474A1 (es)
CL (1) CL2023001836A1 (es)
IL (1) IL303776A (es)
MX (1) MX2023007420A (es)
TW (1) TW202241423A (es)
WO (1) WO2022140258A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926828T3 (es) 2014-09-29 2022-10-28 Chemocentryx Inc Procesos e intermedios en la preparación de antagonistas de C5aR
US20170202821A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160060351A1 (en) * 2013-05-08 2016-03-03 Novo Nordisk A/S Use of C5AR Antagonists
US20170202821A1 (en) * 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
NZ747259A (en) * 2016-04-04 2022-11-25 Chemocentryx Inc Soluble c5ar antagonists

Also Published As

Publication number Publication date
CN116635075A (zh) 2023-08-22
TW202241423A (zh) 2022-11-01
WO2022140258A1 (en) 2022-06-30
AU2021410668A1 (en) 2023-07-06
US20220257580A1 (en) 2022-08-18
EP4262800A1 (en) 2023-10-25
JP2024500752A (ja) 2024-01-10
CA3205474A1 (en) 2022-06-30
MX2023007420A (es) 2023-06-29
IL303776A (en) 2023-08-01
KR20230124981A (ko) 2023-08-28

Similar Documents

Publication Publication Date Title
CL2023001836A1 (es) Tratamiento de glomerulopatía c3 usando un inhibidor de c5a
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
ZA201804513B (en) Method of treating c3 glomerulopathy
EA202190630A1 (ru) Способы комбинированной терапии
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
TWD196868S (zh) 超音波治療手持件
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022000845A (es) Compuestos inhibidores.
MX2021002556A (es) Tratamiento del dolor postquirurgico.
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
MX2022000143A (es) Metodos novedosos.
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном